Molecular design based on 3D-pharmacophore. Application to 5-HT subtypes receptors

Journal of Chemical Information and Computer Sciences

Volumn 42, Issue 2, 2002, Pages 429-436

  Bureau, Ronan ^a   Daveu, Cyril ^a   Lancelot, Jean Charles ^a   Rault, Sylvain ^a  

^a CENTRE D ETUDES ET DE RECHERCHE SUR LE MÉDICAMENT DE NORMANDIE   (France)

Author keywords

[No Author keywords available]

Indexed keywords

PHARMACOPHORES;

AMINES; CATALYSTS; CONFORMATIONS; ENZYME INHIBITION; MOLECULAR STRUCTURE; TOPOLOGY;

PHARMACODYNAMICS;

SEROTONIN RECEPTOR; SEROTONIN UPTAKE INHIBITOR;

ARTICLE; CHEMISTRY; CLASSIFICATION; DRUG DESIGN;

DRUG DESIGN; RECEPTORS, SEROTONIN; SEROTONIN UPTAKE INHIBITORS;

EID: 0036489463     PISSN: 00952338     EISSN: None     Source Type: Journal    
DOI: 10.1021/ci0101004     Document Type: Article

References (23)

1. Korolkovas, A. Essentials of Molecular Pharmacology, Background for drug design; New York: Interscience: 1970.
2. Gund, P. Three-dimensional pharmacophore pattern searching. In progress in molecular and Subcellular Biology; Hahn, F.E., Ed.; Springer-Verlag: Berlin, 1977; Vol. 5, pp 117-143.
3. Gund, P. Pharmacophoric pattern searching and receptor mapping. Ann. Reports Med. Chem. 1979, 14, 299-308.
4. Humblet, C.; Marshall, G.R. Pharmacophore identification of receptor mapping. Ann. Reports. Med. Chem. 1980, 15, 267-276.
5. CATALYST Version 4.5 software; ACCELRYS, 2001.
6. Hoyer, D.; Clarke, D.E.; Fozard, J.R.; Harting, P.R.; Martin, G.R.; Mylecharane, E.J.; Saxena, P.R.; Humphrey, P.P. International Union of Pharmacology Classification of Receptors for 5-Hydroxytryptamine (Serotonin). Pharmacol. Rev. 1994, 46, 157-203.
7. Zifa, E.; Fillion, G. 5-Hydroxytryptamine Receptors. Pharmacol. Rev. 1992, 44, 401-458.
8. Peroutka, S.J. 5-Hydroxytryptamine receptor subtypes. In Serotonin receptors and their ligands; Olivier, B., Van Wijngaarden, I., Soudijn, W., Eds.; Elsevier (pharmacochemistry library): Amsterdam, 1997; Vol. 27, pp 3-13.
9. 3 Receptors. Part 1. Synthesis and Biological Evaluation of Piperazinopyrro-lothienopyrazines. J. Med. Chem. 1996, 39, 2068-2080.
10. 3 Receptors. Part 2. Synthesis and Biological Evaluation of Piperazinopyridopyrrolopyrazines, Piperazinopyrroloquinoxalines, and piperazinopyridopyrroloquinoxalines. J. Med. Chem. 1997, 40, 1808-1819.
11. Daveu, C.; Bureau, R.; Baglin, I.; Prunier, H.; Lancelot, J.C.; Rault, S. Definition of a pharmacophore for partial agonists of serotonin 5-HT3 receptors. J. Chem. Inf. Comput. Sci. 1999, 39, 362-369.
12. Baglin, I.; Daveu, C.; Lancelot, J.C.; Bureau, R.; Dauphin, F.; Pfeiffer, B.; Renard, P.; Delagrange, P.; Rault, S. First Tricyclo Oximino Derivatives as 5-HT3 ligands. Bioorg. Med. Chem. Lett. 2001, 11, 453-457.
13. Lindberg, U.H.; Thorberg, S.O.; Bengtsson, S.; Renyi, A.L.; Ross, S.B.; Ogren S.O. Inhibitors of neuronal monoamine uptake. 2. Selective inhibition of 5-hydroxytryptamine uptake by alpha-amino acid esters of phenethyl alcohols. J. Med. Chem. 1978, 21, 448-456.
14. Humber, L.G.; Lee, D.; Rakhit, S.; Treasurywala, A.M. Computer-assisted investigation of structure-activity relationships in serotonin-uptake blockers. J. Molecular Graphics 1985, 3, 84-89.
15. Rupp, A.; Kovar, K.A.; Beuerle, G.; Ruf, C.; Folkers G. A new pharmophoric model for 5-HT reuptake-inhibitors: differentiation of amphetamine analogues. Pharm. Acta Helv. 1994, 68, 235-244.
16. Hoepping, A.; Johnson, K.M.; George, C.; Flippen-Anderson, J.; Kozikowski, A.P. Novel conformationally constrained tropane analogues by 6-endo-trig radical cyclization and stille coupling - switch of activity toward the serotonin and/or norepinephrine transporter. J. Med. Chem. 2000, 43, 2064-2071.
17. Brooks, B.R.; Bruccoleri, R.E.; Olafson, B.D.; Sates, D.J.; Swaninathan, S.; Karplus, M. CHAMM: A program for macromolecular energy, minimization, and dynamics calculations. J. Comput. Chem. 1983, 4, 187-217.
18. Smellie, A.; Teig, S.L.; Towbin, P. Poling: Promoting Conformational Variation. J. Comput. Chem. 1995, 16, 171-187.
19. Güner, O.F. Pharmacophore, Perception, Development, and Use in Drug Design; IUL Biotechnology Series, 2000; p 504.
20. Fisher, R. The design of Experiments; Hafner Publishing: New York, 1966; Chapter 2.
21. Stinson, S.C. Counting on Chiral Drugs. Special report 1998; Vol. 76, pp 1-136. http://pubs.acs.org/hotartcl/cenear/980921/drugs.html.
22. CERIUS2, Version 4.5 software; ACCELRYS, 2001.
23. Rohrbaugh, R.H.; Jurs, P.C. Descriptions of molecular shape applied in studies of structure/activity and structure/property relationships. Anal. Chim. Acta 1987, 199, 99-109.